Building Blocks Catalog

300 Thousand compounds in stock

Original and unique

Make-on-demand
Building Blocks

1B novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Library Synthesis

48B Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from February 2024

Recent News

  • 27 March 2024   Press Release

    Enamine Announces Expansion of Its Library Synthesis Capabilities

    March, 2024, Kyiv, Ukraine. Enamine Ltd, the global leader in supplying small molecules and early drug discovery services, announces the expansion of its library synthesis capabilities with a focus on Enamine REAL compounds to further support the growing demands of agricultural and pharmaceutical companies, research institutes, and drug discovery centers.

  • 01 March 2024   News

    Enamine and Genez International Announce Strategic Collaboration to Launch ...

    We are excited to announce a strategic collaboration between Enamine, the world's leading provider of chemical building blocks, compound libraries, and biology services, and Genez International, a prominent enterprise with 15 years of experience in cross-border supply management, biopharmaceutical research and development, semiconductor equipment, and high-definition digital imaging systems.

  • 21 February 2024   Press Release

    Cresset Announces Global Collaboration With Enamine on New Virtual ...

    Cresset recently announced a collaboration with Enamine, the world’s leading provider of chemical building blocks and drug discovery services to develop innovative new solutions for the early drug discovery process.

Upcoming events

From 01/01/2016 Enamine has been acting as a project coordinator of a four year-long PELICO project, funded under the European Union’s Marie Skłodowska-Curie fellowship programme - within the framework of Horizon 2020.

The EU-funded PELICO project has been developing peptidomimetics that can switch between two forms: either biologically inactive or biologically active when exposed to light of specific wavelengths.

The PELICO team is carrying out work in four main areas. The first stage includes carrying out pharmacokinetic and toxicity studies of photo-controlled peptidomimetics synthesised under previous research. Next, novel photo-controlled building blocks are evaluated to ascertain their compatibility with peptides. Then, new photo-controlled peptidomimetics are created, based on these novel building blocks.

PELICO researchers believe this new approach represents a breakthrough in the design, synthesis and application of peptide analogues. Initial testing is being carried out with a special emphasis on antimicrobial and cancer treatments.

Up to date, the project implementation has yielded promising research results, facilitated by a highly positive impact of Enamine as a COO.

FOLLOW US